Tuesday, February 20, 2018 11:59:11 PM
It is good but I have seen better and combined with the lack of detail about the patients response leads me to conclude there may be more non-responders or low responders than many believe. If you have good data, you report it. They didn't, so one should reasonably be a bit skeptical until the company shares the data.
I am sure you recognize that the words in these press releases are very carefully chosen. They don't talk about filing a BLA and that is huge. They do talk about the mono trial and that tells me the data is not good enough for pursuing a BLA for combo (or the economics of it no longer make any sense) and can only be helpful for mono recruiting. Everyone will need to make their own judgment on this but I think it is very reasonable to read between the lines that there is some issue with the data.
CYDY was barely getting any money from PAulsen clients with each new round until this most recent one. That leads me to believe they must have given some pretty heavy hints that the data might be good in order to get the $10 million just before the critical data is released.
If that is true, the investors supplying the $10 million might well feel aggrieved and pursue legal action. Hardly seems like a baffling situation to me but each person has to draw their own conclusions and since we don't have all the needed info, people will reach different conclusions.
I agree with you on this. Those were horrible terms and to sell those shares and warrants just before the data release with the huge potential dilution coming from the conversion of the warrants just ahead. This management team is evidently not as confident in the future as many believe.
Here I just disagree straightforwardly with you and think the absence of BLA in the press release where key data is revealed is telling. The previous comments were made prior to the data. Since they did not mention it in the press release once the data was known seems like a very, very significant matter.
That plus there may be some shorting by some who hold warrants and plan to convert them. By shorting on the data release bounce, they lock in a profit on the warrant conversion.
I didn't accuse anyone, just urged that attitude since I knew my comments would not be welcome by many.
Recent CYDY News
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 10/11/2024 01:00:15 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 10/01/2024 09:15:42 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 09/30/2024 09:01:16 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/13/2024 04:15:06 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 09/07/2024 12:44:56 AM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 09/07/2024 12:42:22 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 08/15/2024 09:21:30 PM
- Form SC TO-I/A - Tender offer statement by Issuer: [Amend] • Edgar (US Regulatory) • 07/22/2024 01:00:58 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 07/09/2024 09:17:48 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 07/09/2024 09:16:28 PM
- Form SC TO-I/A - Tender offer statement by Issuer: [Amend] • Edgar (US Regulatory) • 07/09/2024 09:16:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/09/2024 12:46:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 09:15:10 PM
- Form SC TO-I - Tender offer statement by Issuer • Edgar (US Regulatory) • 06/03/2024 09:10:56 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/06/2024 09:17:30 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/06/2024 09:16:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 09:09:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2024 02:30:20 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/01/2024 10:16:47 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/01/2024 10:15:34 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/22/2024 10:16:11 PM
ZenaTech, Inc. (NASDAQ: ZENA) Launchs IQ Nano Drone for Commercial Indoor Use • HALO • Oct 10, 2024 8:09 AM
CBD Life Sciences Inc. (CBDL) Targets Alibaba as the Next Retail Giant for Wholesale Expansion of Top-Selling CBD Products • CBDL • Oct 10, 2024 8:00 AM
Foremost Lithium Announces Option Agreement with Denison on 10 Uranium Projects Spanning over 330,000 Acres in the Athabasca Basin, Saskatchewan • FAT • Oct 10, 2024 5:51 AM
Element79 Gold Corp. Reports Significant Progress in Community Relations and Development Efforts in Chachas, Peru • ELEM • Oct 9, 2024 10:30 AM
Unitronix Corp Launches Share Buyback Initiative • UTRX • Oct 9, 2024 9:10 AM
BASANITE INDUSTRIES, LLC RECEIVES U.S. PATENT FOR ITS BASAFLEX™ BASALT FIBER COMPOSITE REBAR AND METHOD OF MANUFACTURING • BASA • Oct 9, 2024 7:30 AM